SCHEMBL6038726

SCHEMBL6038726

O=S(=O)(Nc1nc2ccccc2nc1OCCN1CCOCC1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.60
LMNA P02545 2/20 0.60
HSD17B10 Q99714 2/20 0.60
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
NPSR1 Q6W5P4 2/20 0.50
MAPT P10636 2/20 0.48
GAA P10253 2/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
TOP2A P11388 1/20 0.45
PIK3CG P48736 1/20 0.45
HPGD P15428 1/20 0.45
GNRHR P30968 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038773 0.92 MEN1 (0.52) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038901 0.92 MEN1 (0.54) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6039360 0.90 KMT2A (0.55) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038525 0.89 KDM4E (0.50) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038533 0.89 MEN1 (0.49) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038589 0.89 KDM4E (0.62) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6039281 0.86 KDM4E (0.62) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038833 0.84 KDM4E (0.61) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6039203 0.81 MEN1 (0.56) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL6038375 0.81 MEN1 (0.53) KDM4ELMNAHSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
US-20060004019-A1 Steroid sparing agents and methods of using same BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KDM4E 3561/4885LMNA 4821/4885HSD17B10 2083/4885
US-20060004019-A1 Steroid sparing agents and methods of using same IL5, FCER2, CD40 KDM4E 1953/4885LMNA 4801/4885HSD17B10 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.